1. Home
  2. CVBF vs RYTM Comparison

CVBF vs RYTM Comparison

Compare CVBF & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CVB Financial Corporation

CVBF

CVB Financial Corporation

HOLD

Current Price

$19.53

Market Cap

2.7B

Sector

Finance

ML Signal

HOLD

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$86.65

Market Cap

5.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CVBF
RYTM
Founded
1974
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
5.9B
IPO Year
2009
2017

Fundamental Metrics

Financial Performance
Metric
CVBF
RYTM
Price
$19.53
$86.65
Analyst Decision
Buy
Strong Buy
Analyst Count
3
14
Target Price
$24.17
$131.14
AVG Volume (30 Days)
1.2M
945.1K
Earning Date
04-22-2026
05-06-2026
Dividend Yield
4.10%
N/A
EPS Growth
5.56
28.34
EPS
1.52
N/A
Revenue
N/A
N/A
Revenue This Year
$21.47
$55.17
Revenue Next Year
$15.21
$95.98
P/E Ratio
$12.85
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.01
$45.91
52 Week High
$21.48
$122.20

Technical Indicators

Market Signals
Indicator
CVBF
RYTM
Relative Strength Index (RSI) 52.81 49.59
Support Level $19.18 $84.39
Resistance Level $20.62 $97.19
Average True Range (ATR) 0.44 5.47
MACD 0.10 0.71
Stochastic Oscillator 82.81 54.25

Price Performance

Historical Comparison
CVBF
RYTM

About CVBF CVB Financial Corporation

CVB Financial Corp is the holding company for Citizens Business Bank. Citizens Business Bank offers banking, lending, and investing services. It provides a full complement of lending products, including commercial, agribusiness, consumer, SBA, real estate, and construction loans, as well as equipment and vehicle leasing. Commercial products include lines of credit and other working capital financing, accounts receivable lending and letters of credit.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: